ReviewCurrent molecular medicine2026
Astragalus Mongholicus for Idiopathic Pulmonary Fibrosis Treatment: From Molecules to Systems.
Review in Current molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- BMSCs alleviate inflammation and inhibit apoptosis in radiation pneumonitis treatment by modulating the NF-κB/NLRP3 signaling pathway.Journal of radiation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease with limited treatment options. Astragalus mongholicus (AM), a cornerstone herb in traditional Chinese medicine (TCM), demonstrates significant therapeutic potential for IPF due to its multi-target mechanisms. This review synthesizes evidence on AM and its bioactive components; astragalus polysaccharide (APS), astragaloside IV (AS IV), and calycosin (CAL) in targeting key IPF pathological processes. These include suppression of inflammatory responses (via TLR4/NF-κB inhibition), inhibition of extracellular matrix deposition (via MMP/TIMP modulation), attenuation of oxidative stress, regulation of autophagy, and blockade of epithelial-mesenchymal transition (via lncRNA-ATB/miR-200c/ZEB1 axis). We further highlight the integration of molecularlevel mechanisms with systems pharmacology to elucidate AM's holistic actions. Clinical studies support AM-containing TCM prescriptions in improving lung function with fewer adverse effects. This synthesis underscores AM's promise as a multi-target therapeutic agent and advocates for systematic pharmacology approaches in future IPF drug development.
Indexed as
Identifiers
41031494What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.